Compensation

Cytokinetics Investors Urged to Act as Lead‑Plaintiff Deadline Nears in REMS‑Related Securities Suit

The pending Northern District of California case challenges disclosures about Cytokinetics’ aficamten review after an FDA‑requested REMS delayed the timeline.